BioTime (Israel) Performance

BTX -- Israel Stock  

ILS 500.20  5.60  1.11%

Macroaxis gives BioTime performance score of 0 on a scale of 0 to 100. The firm shows Beta (market volatility) of -0.75 which signifies that as returns on market increase, returns on owning BioTime are expected to decrease at a much smaller rate. During bear market, BioTime is likely to outperform the market.. Even though it is essential to pay attention to BioTime historical returns, it is always good to be careful when utilizing equity current trending patterns. Macroaxis philosophy towards foreseeing future performance of any stock is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. BioTime exposes twenty-one different technical indicators which can help you to evaluate its performance. BioTime has expected return of -1.5066%. Please be advised to confirm BioTime Jensen Alpha as well as the relationship between Potential Upside and Skewness to decide if BioTime past performance will be repeated at some point in the near future.
Horizon     30 Days    Login   to change

BioTime Relative Risk vs. Return Landscape

If you would invest  76,220  in BioTime on November 10, 2018 and sell it today you would lose (26,200)  from holding BioTime or give up 34.37% of portfolio value over 30 days. BioTime is producing return of less than zero assuming 4.4996% volatility of returns over the 30 days investment horizon. Simply put, 40% of all equities have less volatile historical return distribution than BioTime and 99% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 
Assuming 30 trading days horizon, BioTime is expected to under-perform the market. In addition to that, the company is 3.45 times more volatile than its market benchmark. It trades about -0.33 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.04 per unit of volatility.

BioTime Market Risk Analysis

Sharpe Ratio = -0.3348
Good Returns
Average Returns
Small Returns
Negative ReturnsBTX

BioTime Relative Performance Indicators

Estimated Market Risk
  actual daily
 40 %
of total potential
Expected Return
  actual daily
 0 %
of total potential
Risk-Adjusted Return
  actual daily
 0 %
of total potential
Based on monthly moving average BioTime is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioTime by adding it to a well-diversified portfolio.

BioTime Performance Rating

BioTime Risk Adjusted Performance Analysis


Risk-Adjusted Performance

Over the last 30 days BioTime has generated negative risk-adjusted returns adding no value to investors with long positions.

BioTime Alerts

Equity Alerts and Improvement Suggestions

BioTime is not yet fully synchronised with the market data
BioTime generates negative expected return over the last 30 days
BioTime has high historical volatility and very poor performance
The company reported revenue of 5.23M. Net Loss for the year was (72.97M) with profit before overhead, payroll, taxes, and interest of 3.29M.
BIOTIME has accumulated about 21.44M in cash with (30.75M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.17.
Roughly 46.0% of the company shares are held by company insiders
Latest headline from Channing Capital Management Increases Stake in Philip Morris International In Mason Street Advisors Has Lowered Position in 3 by 316,199 as Market Valuation Rose - D Minute

BioTime Performance Indicators

BioTime Basic Price Performance Measures

Quick Ratio7.80
Fifty Two Week Low561.50
Fifty Two Week High1,113.00
Check also Trending Equities. Please also try Piotroski F Score module to get piotroski f score based on binary analysis strategy of nine different fundamentals.